# A Study to Investigate the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of PG-102 (MG12) in Healthy Adult and Obesity Participants.

> **NCT06309667** · PHASE1 · COMPLETED · sponsor: **ProGen. Co., Ltd.** · enrollment: 102 (actual)

## Conditions studied

- Healthy
- Overweight

## Interventions

- **DRUG:** PG-102(MG12)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06309667
- **Lead sponsor:** ProGen. Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-04
- **Primary completion:** 2025-02-05
- **Final completion:** 2025-02-05
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2025-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06309667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06309667, "A Study to Investigate the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of PG-102 (MG12) in Healthy Adult and Obesity Participants.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06309667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*